A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure. A Report From the Carvedilol Or Metoprolol European Trial (COMET)

Journal of the American College of Cardiology

Volumn 47, Issue 8, 2006, Pages 1603-1611

  Cleland, John G F ^a   Charlesworth, Andrew ^b   Lubsen, Jacobus ^c   Swedberg, Karl ^d   Remme, Willem J ^e   Erhardt, Leif ^f   Di Lenarda, Andrea ^g   Komajda, Michel ^h   Metra, Marco ⁱ   Torp Pedersen, Christian ^j   Poole Wilson, Philip A ^k  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Nottingham Clinical Research Group   (United Kingdom)

^c SOCAR RESEARCH SA   (Switzerland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Sticares Cardiovascular Research Foundation   (Netherlands)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF TRIESTE   (Italy)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j BISPEBJERG HOSPITAL   (Denmark)

^k NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME; WELLBEING;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646048754     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.069     Document Type: Article

References (18)

1. Cleland J.G.F. How to assess new treatments for the management of heart failure. composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 4 (2002) 243-247
2. Lubsen J., and Kirwan B.A. Combined endpoints. can we use them?. Stat Med 21 (2002) 2959-2970
3. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 7 (2002) 176-182
4. Pfeffer M.A., Swedberg K., Granger C.B., et al., CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure. the CHARM-Overall programme. Lancet 362 (2003) 759-766
5. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
6. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al., COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). randomised controlled trial. Lancet 362 (2003) 7-13
7. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
8. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
9. Cleland J.G.F., Coletta A., Nikitin N., Louis A., and Clark A.L. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-Wave Alternans. Eur J Heart Fail 5 (2003) 389-394
10. Olsson G., Lubsen J., van Es R.F., and Rehnqvist N. Quality of life after myocardial infarction. effect of long term metoprolol on mortality and morbidity. BMJ 292 (1986) 1493
11. Prieto L., and Sacristan J.A. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1 (2003) 80
12. Poole-Wilson P.A., Cleland J.G.F., Hanrath P., et al., COMET Study Investigators. Rationale and design of the Carvedilol or Metoprolol European Trial in patients with chronic heart failure. the COMET trial. Eur J Heart Fail 4 (2002) 321-329
13. Cleland J.G.F., Goode K., Erhardt L., et al., COMET Investigators. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther 18 (2004) 139-152
14. Glick H., Cook J., Kinosian B., et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure. an economic analysis of the Studies Of Left Ventricular Dysfunction (SOLVD) treatment trial. J Cardiac Fail 1 (1995) 371-380
15. Rogers W.J., Johnstone D.E., Yusuf S., et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril. the studies of left ventricular dysfunction. J Am Coll Cardiol 23 (1994) 393-400
16. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342 (1993) 1441-1446
17. Calvert M., Freemantle N., and Cleland J.G.F. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF Study. Eur J Heart Fail 7 (2005) 243-251
18. Cleland J.G.F., Daubert J.C., Erdmann E., et al. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 7 (2005) 205-214